FDA Approves Johnson & Johnson’s Chemotherapy-free Lung Cancer Combo Treatment
The combination regimen was approved for the first-line treatment of adults with locally advanced or metastatic non-small cell lung cancer with specific EGFR mutations.
Tag: Johnson and Johnson
All
Latest
All
Latest
FDA Approves Rybrevant for Certain NSC Lung Cancer Patients
The FDA has approved Janssen Pharma's Rybrevant (amivantamab-vmjw) as the first treatment for adult patients with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
All
Latest
J&J Single-dose Vaccine 85% Effective Preventing Severe COVID-19
The vaccine candidate had an 85% overall efficacy at preventing severe disease 28 days after vaccination and a 66% overall efficacy rate in preventing moderate-to-severe COVID-19.
